Padagis is a global provider of generic pharmaceuticals focused on topical and other non-oral prescription and over-the-counter products. Its technical work spans topical and transdermal drug delivery, nasal formulations, non-oral formulation development and pharmaceutical manufacturing. Products in its portfolio include creams, ointments, gels, foams, sprays, patches, nasal treatments and suppositories, developed for both prescription and over-the-counter use.
A substantial part of the company's development activity concerns Paragraph IV abbreviated new drug applications, which involve navigating the patent position of branded pharmaceuticals. The company also produces a naloxone nasal spray used in opioid overdose response. Formulation and manufacturing work is carried out against standards of safety and efficacy, with the stated aim of reducing healthcare costs and widening access to affordable medicines.
Padagis operates with a team distributed across the United States and Israel and sells into global markets. Its stated values centre on innovation, reliability and accessibility for patients and healthcare providers.
